[{"id":"96f0f596-bee1-42fc-9dcc-41fcf8f78f40","acronym":"SL03-OHD-105","url":"https://clinicaltrials.gov/study/NCT05483933","created_at":"2022-08-02T12:55:49.417Z","updated_at":"2025-02-25T15:27:30.695Z","phase":"Phase 1","brief_title":"Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers","source_id_and_acronym":"NCT05483933 - SL03-OHD-105","lead_sponsor":"Shattuck Labs, Inc.","biomarkers":" FOLR1","pipe":" | ","alterations":" FOLR1 expression","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • SL-172154"],"overall_status":"Completed","enrollment":" Enrollment 86","initiation":"Initiation: 08/18/2022","start_date":" 08/18/2022","primary_txt":" Primary completion: 02/07/2025","primary_completion_date":" 02/07/2025","study_txt":" Completion: 02/07/2025","study_completion_date":" 02/07/2025","last_update_posted":"2025-02-11"},{"id":"f1031737-80a9-4c8b-a2a6-14dc6ec95216","acronym":"SL03-OHD-104","url":"https://clinicaltrials.gov/study/NCT05275439","created_at":"2022-03-11T15:53:40.765Z","updated_at":"2025-02-25T15:44:45.150Z","phase":"Phase 1","brief_title":"Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects with MDS or AML","source_id_and_acronym":"NCT05275439 - SL03-OHD-104","lead_sponsor":"Shattuck Labs, Inc.","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • SL-172154"],"overall_status":"Completed","enrollment":" Enrollment 106","initiation":"Initiation: 03/17/2022","start_date":" 03/17/2022","primary_txt":" Primary completion: 02/06/2025","primary_completion_date":" 02/06/2025","study_txt":" Completion: 02/06/2025","study_completion_date":" 02/06/2025","last_update_posted":"2025-02-11"},{"id":"b8e5058b-32bb-4610-b262-21974b89110e","acronym":"SL03-OHD-101","url":"https://clinicaltrials.gov/study/NCT04406623","created_at":"2021-01-18T21:14:44.896Z","updated_at":"2025-02-25T17:30:15.356Z","phase":"Phase 1","brief_title":"Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer","source_id_and_acronym":"NCT04406623 - SL03-OHD-101","lead_sponsor":"Shattuck Labs, Inc.","biomarkers":" HRD","pipe":" | ","alterations":" HRD","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SL-172154"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 06/29/2020","start_date":" 06/29/2020","primary_txt":" Primary completion: 02/02/2023","primary_completion_date":" 02/02/2023","study_txt":" Completion: 02/02/2023","study_completion_date":" 02/02/2023","last_update_posted":"2025-01-30"}]